The Committee is responsible for preparing the European Medicines Agency’s (EMA) opinions on all questions concerning medicinal products for human use, in accordance with Regulation (EC) No 726/2004.

His office and the EMA's Committee for Orphan Medicinal Products also have monthly teleconferences, allowing for the two agencies to discuss the product pipeline. Even though the agencies are ...

has granted Orphan Medicinal Product Designation (OMPD) to elraglusib, a novel GSK-3β inhibitor, for the treatment of pancreatic ductal adenocarcinoma (PDAC). “With limited treatment options ...

X4 Pharmaceuticals (XFOR) announced that its Marketing Authorization Application for mavorixafor for the treatment of WHIM syndrome, a rare ...